Biopharma
The best operating asset in pharma trading at a price that already imputes a $150B+ obesity TAM — own it on the franchise and the orforglipron/retatrutide optionality, but size for a multiple that compresses from ~30x forward as the price war and TAM-skeptic camp grind on the narrative.
Research
The verdict
The best operating asset in pharma trading at a price that already imputes a $150B+ obesity TAM — own it on the franchise and the orforglipron/retatrutide optionality, but size for a multiple that compresses from ~30x forward as the price war and TAM-skeptic camp grind on the narrative.
Eli Lilly is, as of mid-2026, the most valuable pharmaceutical company in history and the 15th most valuable company in the world, with a market cap that crossed $1 trillion in June 2026 (all-time high $1,182.73 on 2026-06-08). Founded 1876, Indianapolis. It is a discover-develop-manufacture-and-sell integrated pharma — it owns the molecule from medicinal chemistry through global commercialization, and (critically for this name) increasingly owns the manufacturing plant too.
The business is, right now, overwhelmingly an incretin company wearing a diversified-pharma costume. The growth engine is a single molecule — tirzepatide, a dual GIP/GLP-1 receptor agonist — sold under two brands:
Together tirzepatide is running at roughly a $50B+ annualized run-rate. For scale: total company revenue was $19.8B in Q1 2026 (+56% YoY), so tirzepatide is ~65% of the company.
The rest of the company is a genuine, if overshadowed, diversified franchise:
Customers: payers (commercial insurers, PBMs, and — newly material in 2026 — Medicare Part D), national health systems (NRDL in China for Mounjaro), and an unusually large and growing cash-pay/DTC channel via LillyDirect. Suppliers: API is increasingly in-house (the $50B+ manufacturing build); fill-finish and devices via CDMO partners. Competitors: the duopoly counterparty is Novo Nordisk (semaglutide — Ozempic/Wegovy/Rybelsus + the oral Wegovy pill + CagriSema); behind them, Amgen (MariTide), Roche, Viking Therapeutics, Structure, and the compounded/generic GLP-1 flood in markets like India.
Contract/payment structure: classic pharma — no take-or-pay, but the obesity franchise is shifting toward net-price compression as the dominant variable. Q1 2026 growth was "strong demand partially offset by lower realized prices" on both Mounjaro and Zepbound — volume is outrunning price erosion, but the spread is the whole game (see Lens 13).
Upstream → Lilly → patient, with named chokepoints:
Upstream inputs. Peptide API (tirzepatide is a synthetic peptide) requires large-scale solid-phase/liquid-phase peptide synthesis capacity — historically the binding constraint for the entire GLP-1 class and the reason both Lilly and Novo spent 2023-2025 on FDA shortage lists. Lilly's answer is vertical integration: it has announced >$50B in US manufacturing investment since 2020 (~$23B of it in net-new plants/expansions), with six new plants and three of the future sites dedicated to API for tirzepatide.
The orforglipron supply twist — a structural advantage. Orforglipron is a small molecule, not a peptide. It is made by conventional small-molecule chemical synthesis, which is dramatically cheaper and more scalable than peptide synthesis and is not constrained by the peptide-API bottleneck. This is the single most important supply-chain fact in the whole dossier: it lets Lilly manufacture an oral GLP-1 at a cost structure and volume ceiling that injectable peptides — including Novo's injectable semaglutide and even Novo's peptide oral semaglutide — cannot match. Lilly pre-built $1.5B of Foundayo inventory ahead of the April 2026 launch specifically to avoid repeating the injectable shortage.
Downstream. Distribution via traditional pharmacy/wholesaler channel plus the company-owned LillyDirect DTC platform (Zepbound $299-$499/mo cash) and the new federal TrumpRx channel (Zepbound ~$346/mo). The DTC channel disintermediates PBMs — strategically important because it lets Lilly set net price directly and capture cash-pay demand the insured channel misses.
Single-source / chokepoint read: the historical chokepoint (peptide API) is being engineered away with capital; the orforglipron small-molecule route removes it entirely for the oral franchise. The residual risk is execution — bringing $50B of greenfield capacity online on schedule (Lebanon end-2026 is the near tell) and the fill-finish/device supply for injectables. Manufacturing execution is now a top-3 risk because the company has chosen to make it the moat (Lens 13).
Four stacked moats, in descending durability:
Best-in-class efficacy (the molecule moat). This is the deepest and most underappreciated. On weight loss, the efficacy ladder is now: tirzepatide (~21-23% in SURMOUNT) > semaglutide (~15%) — head-to-head, SURMOUNT-5 showed tirzepatide superior to semaglutide. Then CagriSema (Novo's next-gen) failed to demonstrate non-inferiority to tirzepatide at 84 weeks (Feb 2026), capping at ~23% — i.e. Novo's best future drug could not beat Lilly's current drug. And waiting behind tirzepatide is retatrutide at 30.3% at 104 weeks — bariatric-surgery-level (Lens 5). Lilly has the #1 and the #2 drug in the category, and the #2 is unlaunched. Efficacy leadership compounds: it wins formulary preference, share, and pricing power.
The oral franchise / small-molecule cost moat. Orforglipron is the first and (with oral semaglutide) one of only two approved oral GLP-1s — and the only one with no food/water/timing restriction, because its non-peptide structure needs no absorption enhancer. Goldman models Lilly at 60% of the daily-oral segment by 2030 ($13.6B) vs Novo oral semaglutide ~21%. The cost-to-manufacture advantage of a pill vs an injectable peptide is the moat that survives the price war.
Manufacturing scale + vertical integration. $50B of owned capacity is a capital moat a new entrant cannot replicate on any relevant timescale, and it converts the historical industry weakness (supply) into Lilly's relative strength.
Patent estate (the legal moat, time-boxed). Tirzepatide molecule patent to Jan 2036, formulation patents to Jun 2039, follow-on filings cited out to 2041 (53 US applications, 16 granted). ~10-13 years of runway — long, but finite and the subject of patent-thicket criticism (Lens 10/13).
Bargaining power: over patients/prescribers — high (best efficacy, demand >> supply for years). Over payers — deteriorating, and this is the crux. With Medicare now covering obesity GLP-1s at a negotiated ~$245/mo base and a $50 copay cap (mid-2026), and a public price war underway, the payer relationship is shifting from "Lilly sets price" to "government/PBM negotiates price." Volume power up, price power down.
Lilly does not report clean obesity-vs-diabetes-vs-other GAAP segments the way a multi-division industrial does; the public disclosure is by product and by geography. Web-sourced build (re-ground against segments.csv when the research layer exists):
By product (Q1 2026, worldwide unless noted):
| Product | Q1 2026 rev | YoY | Note |
|---|---|---|---|
| Mounjaro (T2D) | $8.7B | +125% | US $4.2B (+59%), OUS $4.4B (from $1.2B) — OUS is the acceleration story |
| Zepbound (obesity) | $4.1B (US) | +79% | US figure; OUS still ramping |
| Everything else | ~$7B | — |
Trend & cause: the defining segment dynamic is OUS Mounjaro inflecting — international revenue went from $1.2B (Q1'25) to $4.4B (Q1'26) as ex-US launches and the China NRDL listing took hold. This is accelerating and is the next leg after US saturation begins. The offsetting force inside every product line is negative price/mix (lower realized prices on both brands), which is why revenue +56% but the quality of that growth (volume-led, price-pressured) matters for the forward margin.
By geography: US still the majority but the growth delta is now international. The China NRDL listing trades price for volume — a deliberate land-grab.
Whole-company context: FY2025 total revenue $65.18B (+45% from $45.04B); the 45% was "driven by Mounjaro and Zepbound." So at both the quarter and the year, this is a one-molecule growth story with a solid diversified base underneath.
Headline: Revenue $19.8B (+56% YoY); non-GAAP EPS $8.26 (+170% YoY). A clear beat — the stock rose on the print.
Unusual vs own history: the magnitude is the anomaly — a $1T-cap company growing revenue 56% is nearly unprecedented at this scale. The watch-item is the widening gap between reported volume strength and realized-price softness.
This is where the big-cap-pharma exception earns its keep: Lilly's multiple is not justified by the current P&L alone, it's justified by the pipeline that turns one molecule into a metabolic-disease platform. The asset table, by phase, mid-2026:
| Program | Indication(s) | Mechanism / modality | Phase / status | Pleiotropic profile | Next value event |
|---|---|---|---|---|---|
| Tirzepatide (Mounjaro/Zepbound) | T2D, obesity, OSA, (CV, HFpEF, kidney, MASH in trials) | GIP/GLP-1 dual, injectable peptide | Marketed; label-expanding | OSA approved (AHI −2/3, SURMOUNT-OSA); CV benefit shown (SURPASS-CVOT HR 0.88); SURMOUNT-MMO (5-pt MACE in obesity) ongoing, no readout yet | SURMOUNT-MMO readout = the single biggest label catalyst left for the franchise |
| Orforglipron (Foundayo) | Obesity (approved Apr 2026), T2D (filing 2026) | GLP-1, oral small molecule | APPROVED (obesity, US, 2026-04-01); T2D filing 2026; ACHIEVE-3 beat oral sema | ~12.4% weight loss at top dose; superior glycemic control vs oral semaglutide | T2D approval; OUS approvals; the commercial ramp itself (Lens 13) |
| Retatrutide | Obesity, T2D, MASH, OA, CVD | GIP/GLP-1/glucagon TRIPLE agonist, injectable | Phase 3 (TRIUMPH program); TRIUMPH-1 + TRIUMPH-4 positive; 7 readouts expected in 2026 | 30.3% weight loss @104wk (surgery-level); 86% liver-fat reduction, 93% to normal liver fat (MASLD); OA pain −75.8% WOMAC; glucagon arm drives hepatic fat oxidation | TRIUMPH-2/-3 readouts (2026); FDA filing late-2026/early-2027 |
| Kisunla (donanemab) | Early symptomatic Alzheimer's | Anti-amyloid mAb | Marketed (US 2024, EU/AU 2025-26) | 3-yr data: benefit grows over time; "stop when cleared" dosing | Label/dosing updates; uptake |
| Verzenio (abemaciclib) | Breast/oncology | CDK4/6 inhibitor | Marketed | — | — |
| Remternetug | Alzheimer's (prevention/early) | Next-gen anti-amyloid | Phase 3 | — | Readout |
| Oncology (Scorpion PI3Kα; +3 in Ph3) | Solid tumors | Mutant-selective small molecules | Phase 3 (×4 medicines) | — | Readouts |
| Verve gene-editing | Cardiovascular (lipids) | In-vivo base editing | Acquired (clinical) | One-and-done lipid lowering | Early data |
| Morphic / Omvoh | IBD | α4β7 integrin / IL-23 | Marketed + clinical | — | — |
The pleiotropic thesis Connor cares about, made concrete. The reason GLP-1/incretins are a platform and not a diet drug is that the same mechanism keeps reading out positive on adjacent organ systems, each one a new multi-billion TAM:
n/a as a Lilly-specific clinical result.The point: each pleiotropic indication is a separate label, a separate payer argument, and a separate TAM. The bear case (Lens 13) is fundamentally a bet that the valuation already capitalizes all of these; the bull case is that the platform keeps minting indications faster than the multiple can fairly price.
No transcripts/ in the research layer, so this is ``-inferred from release language and coverage across the last ~4 prints (Q2'25 → Q1'26):
Operating comp table (large-cap pharma):
| Company | Ticker | ~Mkt cap | P/E | EV/EBITDA | Note |
|---|---|---|---|---|---|
| Eli Lilly | LLY | ~$1.04-1.07T | TTM ~38-45; Fwd (NTM) ~30.5 | ~36 | The growth premium name |
| Novo Nordisk | NVO | n/a (down sharply post-CagriSema; -16% on 2026-02-23) | n/a | n/a | The direct duopoly comp; de-rated in 2026 |
| Merck | MRK | n/a | n/a | n/a | Keytruda LOE overhang |
| AbbVie | ABBV | n/a | n/a | n/a | Post-Humira |
| Amgen | AMGN | n/a | n/a | n/a | MariTide obesity entrant |
| Roche | RHHBY | n/a | n/a | n/a | CT-388 obesity |
I did not source clean peer multiples for the non-Lilly rows in this web-only pass; rather than fabricate plausible numbers I leave them n/a. The load-bearing fact is the relative one: LLY trades at a large-cap-pharma premium (forward P/E ~30x, EV/EBITDA ~36x) that only the obesity growth justifies. Sector pharma typically sits low-to-mid-teens P/E; Lilly is ~2x that. The entire bull/bear fight is whether that premium is earned.
(Overlay) Mechanism comps — by target, not by P/E:
Pattern over the recent cycle:
David A. Ricks — Chair & CEO since January 2017. The defining fact: he took LLY from a ~$70B market cap to >$1 trillion — a ~14-15x in ~9 years, making Lilly the most valuable pharma in history on his watch. Named CEO of the Year (Chief Executive); among most influential CEOs in oncology.
n/a (would ground against insider-transactions.csv); Ricks's net worth is tracked publicly (GuruFocus) but personal holdings as % of float not sourced here.n/a in this pass (search did not surface a current payout/repurchase policy); to be grounded.No filings in the research layer, so this is a web + first-principles read; re-ground against 10-K/10-Q and run fetch-regulatory-findings.ts when the layer exists.
Regulatory findings (web-only sub-section). No regulatory/regulatory-findings.md was generated (web-only run). Web scan for SEC/FTC/DOJ/FDA enforcement against Eli Lilly surfaced no material 2025-2026 enforcement action, consent decree, or AAER. The live legal/regulatory themes are commercial-policy, not fraud: (1) drug-pricing litigation/negotiation (Medicare negotiation, TrumpRx, the price war) — policy, not enforcement; (2) patent-thicket criticism (i-mak.org alleges "patent abuse" on the 53-application tirzepatide estate) — advocacy, not a finding; (3) ordinary-course product liability / IP litigation disclosed in 10-K Item 3 (not sourced in this pass — flag to pull). Net: no material regulatory or legal red flag found via web search as of 2026-06-15; SEC EDGAR (LR/AAER) and 10-K Item 3 to be verified when the research layer is built.
Base anchor: FY2026 company guidance — revenue $82-85B, non-GAAP EPS $35.50-37.00. FY2025 actual non-GAAP EPS $24.21.
Three-year non-GAAP EPS path (FY2026 → FY2028), every input labeled, output ``:
| FY2026 | FY2027 | FY2028 | |
|---|---|---|---|
| Revenue | $83.5B (mid-guide) | ~$98B | ~$112B |
| Non-GAAP EPS | $36.25 (mid-guide) | ~$44 | ~$53 |
Implied valuation check: at ~$1,131 and base FY2027 EPS ~$44, that's ~25.7x FY27; on FY28 ~$53, ~21.3x. So the stock is not absurd on out-year earnings IF the growth holds — the premium is forward-growth, not bubble-froth. The bear's whole argument is that the out-year EPS is too high because the TAM and price assumptions are too generous.
(Overlay) Catalyst-gated framing. Unlike a pre-revenue biotech, Lilly's "runway to catalyst" is not a cash question (it gushes cash) — it's a narrative-de-risking question. The value-inflection catalysts that convert pipeline optionality into priced-in earnings:
Logged forecast (Brier-scoreable): "LLY FY2027 non-GAAP EPS ≥ $42, p=0.72, resolves 2027-12-31" (base path ~$44 with margin of safety to the threshold). And a clinical binary: "Retatrutide receives FDA filing/submission by end of Q1 2027, p=0.78." (Not logged via forecast.ts — no research layer in this web-only run; record these if/when the topic is registered.)
Bull case. Lilly owns the two best drugs in the largest new therapeutic category in a generation, with the #2 (retatrutide) still unlaunched and the only no-restriction oral pill (Foundayo) just approved. The franchise is being protected by a $50B owned-manufacturing moat and a patent estate to ~2036-39, while the same molecules keep reading out positive on cardiovascular, sleep apnea, liver, kidney and osteoarthritis — each a new multi-billion TAM that the market has only partly capitalized. 83%+ gross margins mean every incremental indication drops to the bottom line. Management is the best operator in pharma. At ~30x forward / ~21x FY28 EPS, a name growing revenue 50%+ is not expensively priced if the platform compounds as it has. The contrarian read: the market is fixated on the price war (a margin question on a 83%-gross-margin business) and the TAM ceiling, while under-pricing the pleiotropic platform — obesity is the wedge, metabolic-and-cardiovascular disease is the prize.
Bear case (2-3 permanent-impairment risks).
Pre-mortem (18 months out, thesis broke): Foundayo's launch disappointed (Novo's first-mover oral pill + the duopoly split the market more evenly than Goldman's 60/40), the price war compressed net price faster than OUS volume could backfill, one of the 7 retatrutide 2026 readouts disappointed (or a tolerability signal emerged at the 30%-weight-loss doses), and the multiple compressed from 30x to 20x as growth normalized — the stock is at $850 not because the business broke but because the expectations did.
Are multiples too high? Not on out-year EPS if the base/bull path holds (~21x FY28). They are too high only in the bear-TAM world. This is a probability-weighted bet on TAM and price, not a valuation absurdity.
Contrarian view the market is refusing to see: the consensus argues obesity-drug pricing; the under-priced variable is the pleiotropic label cascade (SURMOUNT-MMO cardiovascular, MASH, OSA already approved) that turns a price-warred consumer drug into reimbursed chronic-disease standard-of-care — which raises payer willingness and expands TAM in the exact direction the bears are discounting.
Dismantling the bull case:
The best obesity asset not yet owned by Big Pharma — but the market has already priced in a near-perfect Phase 3, leaving a binary 2027 readout where the upside is a takeout and the downside is a trap-door; SC maintenance data in Q3 2026 is the next real tell.
A cash-gushing CF monopoly priced for a successful four-engine diversification (pain, renal, gene therapy, diabetes) that is, so far, only one-third proven — own the moat, underwrite the pipeline at a discount.
Best-in-class *oral* GLP-1 efficacy in the wrong race — Structure has a genuine #2 asset and a fortress balance sheet, but Lilly's orforglipron is already approved (Foundayo, Apr 2026) and Structure's Phase 3 only *starts* Q3 2026, so the bet is whether a 2.9B-cap, ~2030-launch latecomer can carve share against the most powerful franchise in pharma. WATCHING, not yet a position.